Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Efient

- PMLiVE

NICE refuses to back Zaltrap as Sanofi exhausts its options

Patient access scheme and appeal fail to overcome cost concerns

Lilly launches online training to boost patient voice in HTA

New tool aims to help patient advocates 'better influence decisions'

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

EU flag

Bergstrom: Europe must collaborate on medicines value

EFPIA chief says national HTA bodies need to have shared process to assess value of new treatments

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

No price ceiling for rare disease drugs, say MPs

BIA survey comes ahead of consultation on evaluation framework for ultra-orphans

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

NICE and ‘ultra orphans’

NICE and its processes for ‘highly specialised therapies’

- PMLiVE

Lilly/Boehringer’s empagliflozin faces US approval delay

FDA cites manufacturing issues with the new diabetes drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links